Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease

Gráinne S Gorman, Andrew M Schaefer, Yi Ng, Nicholas Gomez, Emma L Blakely, Charlotte L Alston, Catherine Feeney, Rita Horvath, Patrick Yu-Wai-Man, Patrick F Chinnery, Robert W Taylor, Douglass M Turnbull, Robert McFarland, Gráinne S Gorman, Andrew M Schaefer, Yi Ng, Nicholas Gomez, Emma L Blakely, Charlotte L Alston, Catherine Feeney, Rita Horvath, Patrick Yu-Wai-Man, Patrick F Chinnery, Robert W Taylor, Douglass M Turnbull, Robert McFarland

Abstract

Objective: The prevalence of mitochondrial disease has proven difficult to establish, predominantly as a result of clinical and genetic heterogeneity. The phenotypic spectrum of mitochondrial disease has expanded significantly since the original reports that associated classic clinical syndromes with mitochondrial DNA (mtDNA) rearrangements and point mutations. The revolution in genetic technologies has allowed interrogation of the nuclear genome in a manner that has dramatically improved the diagnosis of mitochondrial disorders. We comprehensively assessed the prevalence of all forms of adult mitochondrial disease to include pathogenic mutations in both nuclear and mtDNA.

Methods: Adults with suspected mitochondrial disease in the North East of England were referred to a single neurology center from 1990 to 2014. For the midyear period of 2011, we evaluated the minimum prevalence of symptomatic nuclear DNA mutations and symptomatic and asymptomatic mtDNA mutations causing mitochondrial diseases.

Results: The minimum prevalence rate for mtDNA mutations was 1 in 5,000 (20 per 100,000), comparable with our previously published prevalence rates. In this population, nuclear mutations were responsible for clinically overt adult mitochondrial disease in 2.9 per 100,000 adults.

Interpretation: Combined, our data confirm that the total prevalence of adult mitochondrial disease, including pathogenic mutations of both the mitochondrial and nuclear genomes (≈1 in 4,300), is among the commonest adult forms of inherited neurological disorders. These figures hold important implications for the evaluation of interventions, provision of evidence-based health policies, and planning of future services.

© 2015 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

References

    1. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol 2010;9:829–840.
    1. DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol 2013;9:429–444.
    1. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008;63:35–39.
    1. Whittaker RG, Blackwood JK, Alston CL, et al. Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation. Neurology 2009;72:568–569.
    1. Blakely EL, Yarham JW, Alston CL, et al. Pathogenic mitochondrial tRNA point mutations: nine novel mutations affirm their importance as a cause of mitochondrial disease. Hum Mutat 2013;34:1260–1268.
    1. Office for National Statistics . 2011. Census for England and Wales. Available at: . Accessed on May 21, 2014.
    1. Altman DG. Practical statistics for medical research. 1st ed London, UK; New York, NY: Chapman and Hall, 1991.
    1. Office for National Statistics . 2011. Census: population estimates for the United Kingdom, 27 March 2011. Available at: . Accessed on May 21, 2014.
    1. Man PY, Griffiths PG, Brown DT, et al. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet 2003;72:333–339.
    1. Shoffner JM, Lott MT, Lezza AM, et al. Myoclonic epilepsy and ragged‐red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990;61:931–937.
    1. Taylor RW, Pyle A, Griffin H, et al. Use of whole‐exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA 2014;312:68–77.
    1. Calvo SE, Compton AG, Hershman SG, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next‐generation sequencing. Sci Transl Med 2012;4:118ra10.
    1. Department of Health, Human Fertilisation and Embryology Authority . Innovative genetic treatment to prevent mitochondrial disease. Available at: . Accessed on June 25, 2014.
    1. Norwood FL, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in‐depth analysis of a muscle clinic population. Brain 2009;132(pt 11):3175–3186.
    1. Hao H, Bonilla E, Manfredi G, et al. Segregation patterns of a novel mutation in the mitochondrial tRNA glutamic acid gene associated with myopathy and diabetes mellitus. Am J Hum Genet 1995;56:1017–1025.
    1. Hanna MG, Nelson I, Sweeney MG, et al. Congenital encephalomyopathy and adult‐onset myopathy and diabetes mellitus: different phenotypic associations of a new heteroplasmic mtDNA tRNA glutamic acid mutation. Am J Hum Genet 1995;56:1026–1033.
    1. Chinnery PF, DiMauro S, Shanske S, et al. Risk of developing a mitochondrial DNA deletion disorder. Lancet 2004;364:592–596.
    1. Grady JP, Campbell G, Ratnaike T, et al. Disease progression in patients with single, large‐scale mitochondrial DNA deletions. Brain 2014;137(pt 2):323–334.
    1. Pfeffer G, Gorman GS, Griffin H, et al. Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain 2014;137(pt 5):1323–1336.
    1. Gorman GS, Pfeffer G, Griffin H, et al. Clonal expansion of secondary mitochondrial DNA deletions associated with spinocerebellar ataxia type 28. JAMA Neurol 2015;72:106–111.
    1. Majamaa K, Moilanen JS, Uimonen S, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet 1998;63:447–454.
    1. Office for National Statistics . Ethnicity and National Identity in England and Wales 2011. Available at: . Accessed on June 28, 2014.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe